Patient Care | Clinical Studies | Scientific Research | Education | For Professionals | Support & Resources | Treatment at FWCC | Cancer Survivorship
Feist-Weiller Cancer Center Logo  
Home | Maps & Directions | About Us | Contact | How to Help
Search:    Submit Search
April 24, 2017 - 8:19am | 46°F
   

PARTICIPATE IN A RESEARCH STUDY

When a study involves human subjects the researchers must carefully evaluate what type of individuals should participate in the study and develop inclusion and exclusion criteria to ensure appropriate individuals are enrolled. These criteria are devised for safety purposes and to ensure that the researchers will be able to formulate conclusions based on the data collected.

Each study has a study coordinator who works with the principal investigator to evaluate whether a person meets eligibility criteria.

If you’re interested in participating in a study, click on any of the below links to review the project details. Then contact the study coordinator to learn more about the study and determine whether you’re a good candidate for participation and find out if you meet the inclusion criteria.

 

 Brain Cancer Studies                                        Breast Cancer Studies

 Colon Cancer Studies                                        Gynecologic Cancer Studies

Lung Cancer Studies                                                                   Leukemia Studies                                             

Lymphoma Studies                                             Melanoma Studies                                            

Myeloma Studies                                                            Cancer Control Studies

Liver Cancer  Studies                                                                   Prostate Cancer Studies

Kidney Cancer Studies                                       Stop Smoking for Cancer Survivors

 

  

 Brain Cancer Studies  

  

CDX110-04 Celldex Therapeutics     The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug temozolomide can help improve the life expectancy of patients with newly diagnosed, resected EGFRvIII positive glioblastoma.

The duration of participation in this study may be up to 5 years. After you are screened and enrolled in the study, you will be administered temozolomide and either rindopepimut/GM-CSF or KLH until either disease progression or intolerance to the medications. If your tumor progresses while on this study, your doctor may treat you with other therapies that are not part of the study.

To talk to someone about this study call Janice at 318.813.1403 or email jyager@lsuhsc.edu

ClinicalTrials.gov link:  http://clinicaltrials.gov/ct2/show/NCT01480479

 

  

Breast Cancer Studies 

  

S1007 RxPONDER          The goal is to help doctors and their patients with breast cancer make better treatment decisions by using a genomic test known as the Oncotype DX® Assay.

 

Patients with hormone receptor-positive breast cancer that has spread to their lymph nodes usually get both chemotherapy and hormonal therapy after surgery. But for some of these patients with low to intermediate "recurrence scores" on the Oncotype DX test, chemotherapy may offer little or no benefit. Hormonal therapy alone may be enough.  RxPONDER will measure just how much, if any, benefit these patients get from chemotherapy. And it will try to determine where the cutoff score is between patients who benefit from chemotherapy and patients who do just as well with hormonal therapy alone.

 

To talk to someone about this study call Janice at 318.813.1403 or email jyager@lsuhsc.edu

ClinicalTrials.gov link:  http://clinicaltrials.gov/show/NCT01272037

 

 Colon Cancer Studies

  

S0820 - PACES      Colon cancer chemoprevention study. This phase III clinical trial will enroll about 1,488 volunteers who have recently been treated for colon cancer. The goal is to learn whether by taking the drugs eflornithine and sulindac, these participants can lower their risk of developing new adenomas (precancerous polyps) or a second primary cancer in their colon.

To talk to someone about this study call Kristen at 318.813.1400 or email tkatz@lsuhsc.edu

ClinicalTrials.gov link:  http://clinicaltrials.gov/show/NCT01349881

  

CTSU/C80702 -       This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.  Treatment with celecoxib or placebo continues for 3 years in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for years 2-3, and then annually for 3 years.

To talk to someone about this study call Kristen at 318.813.1400 or email tkatz@lsuhsc.edu

ClinicalTrials.gov link:  http://clinicaltrials.gov/show/NCT01150045

  

S1201:          This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.

 

To talk to someone about this study call Kristen at 318.813.1400 or email tkatz@lsuhsc.edu

ClinicalTrials.gov link:  http://clinicaltrials.gov/show/NCT01498289

 

Liver Cancer Studies

  

E1208:                    This randomized phase III trial is studying chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.

 

To talk to someone about this study call Lori at 318.813.1405 or email tkatz@lsuhsc.edu

ClinicalTrials.gov link: http://clinicaltrials.gov/show/NCT01004978

 

Prostate Cancer Studies

 

 Kidney Cancer Studies

  

S0931:                    Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.  After completion of study treatment, patients are followed up every 6 months for 2 years and then annually for 8 years.

 

To talk to someone about this study call Ryan at 318.675.5655 or email RWilke@lsuhsc.edu

ClinicalTrials.gov link: http://clinicaltrials.gov/show/NCT01120249

 

Gynecologic Cancer Studies

 

Lung Cancer Studies

 

S0819:                    This randomized phase III trial is studying carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or recurrent non-small cell lung cancer.  After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 2 years.

 

To talk to someone about this study call Cindy at 318.813.1406 or email cdiacz@lsuhsc.edu

ClinicalTrials.gov link:         http://clinicaltrials.gov/show/NCT00946712

    

E5508:                              This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer. Some patients undergo blood sample collection at baseline and periodically during study. After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 2-5 years.

To talk to someone about this study call Cindy at 318.813.1406 or email cdiacz@lsuhsc.edu

ClinicalTrials.gov link:          http://clinicaltrials.gov/show/NCT01107626

 

  

Leukemia Studies

  

 

Novartis CAMN107A US28:        A single-arm, open-label, multi-center study of completemolecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+)chronic myelogenous leukemia in chronic phase  

 

To talk to someone about this study call Cindy at 318.813.1406 or email cdiacz@lsuhsc.edu

 

 

S1117:                    To see whether the response rate (complete remission, partial remission, or hematologic improvement) of patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who receive either the combination of lenalidomide and azacitidine or the combination of vorinostat and azacitidine is improved compared to patients who receive single-agent azacitidine.  In all arms, courses repeat every 28 days for up to 5 years.  After completion of study treatment, patients are followed up every 3 months for up to 5 years.

To talk to someone about this study call Cindy at 318.813.1406 or email cdiacz@lsuhsc.edu

ClinicalTrials.gov link:  http://clinicaltrials.gov/show/NCT01522976

  

Lymphoma Studies

 

 

S1108:                    This phase II trial studies how well alisertib works in treating patients with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.  Patients receive alisertib orally twice daily on days 1-7. Treatment repeats every 21 days for 17 courses.  After completion of study treatment, patients are followed up every 4 months for 2 years

To talk to someone about this study call Kristen at 318.813.1400 or email tkatz@lsuhsc.edu

ClinicalTrials.gov link:   http://clinicaltrials.gov/show/NCT01466881

 

 

Melanoma Studies

 

 

E1609 -This phase III clinical trial is studying ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III or stage IV melanoma that has been removed by surgery.  After completion of study therapy, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then yearly for 15 years.

 

To talk to someone about this study call Ryan at 318.675.5655 or email RWilke@lsuhsc.edu

ClinicalTrials.gov link:         http://clinicaltrials.gov/show/NCT01274338

 

 

Myeloma Studies

  

 

Cancer Control Studies

 

  

S1013                               This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.  Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.

 

To talk to someone about this study call Kristen at 318.813.1400 or email tkatz@lsuhsc.edu

ClinicalTrials.gov link:   http://clinicaltrials.gov/ct2/show/NCT01416688

 

Feist-Weiller Cancer Center • 1501 Kings Highway • Shreveport, LA 71103
Privacy Policy
LSU Health Shreveport is an equal opportunity affirmative action institution.
© 2009-2016 LSU Health Shreveport
Search | Contact | Sitemap | LSU Health Shreveport Home
| Email | Webmaster